Abstract: The present disclosure provides TrkA antibodies, compositions comprising such antibodies, and methods of using such antibodies for the prevention and/or treatment of a disease or disorder associated with an inappropriate expression or function of TrkA, such as pain.

Abstract: Provided are novel neutralizing antibodies against spike protein of SARS-COV-2, and the antigen binding fragments thereof. Pharmaceutical composition and kits comprising the same, and the uses thereof are also provided.

Abstract: Provided is an isolated TrkB agonist antibody that binds to an epitope contained in one of the extracellular domains of TrkB and is capable of activating TrkB, wherein the extracellular domains comprises extracellular D1, D2, D3, D4, D5 domains and juxtamembrane domain of TrkB. Methods of using the TrkB agonist antibody in treating or reducing the risk of a TrkB associated conditions in a subject, wherein said condition is selected from cell differentiation, synaptic development, neural injury repairing and/or neurite branching.

Abstract: The present disclosure relates to methods for producing an antibody or an antigen-binding fragment thereof specifically binding to an antigen of interest, methods for inducing proliferation of PBMCs, B cell activation and differentiation, B cell maturation, and/or promoting class switch in an antibody-producing PBMC to produce IgG, compositions for the in vitro immunization and methods for identifying an antibody-enhancing factor for in vitro immunization.

Abstract: The present disclosure provides TrkA antibodies, compositions comprising such antibodies, and methods of using such antibodies for the prevention and/or treatment of a disease or disorder associated with an inappropriate expression or function of TrkA, such as pain.

Abstract: Provided is a novel neutralizing antibody against spike protein of SARS-COV-2, and the antigen binding fragments thereof. Pharmaceutical composition and kits comprising the same, and the uses thereof are also provided.

Abstract: Multiple sound systems are used to provide a realistic audio MR audio experience for one or more users. In one example, an MR space sound system has one or more speakers distributed within an MR space. MR device sound systems for users provides sound directly to the users wearing the MR devices. Audio signals representative of sound in the MR experience are mixed by each sound system to provide sounds that complement each other. Both sound systems provide sound to the users based on events occurring in the MR experience.

Abstract: Multiple sound systems are used to provide a realistic audio MR audio experience for one or more users. In one example, an MR space sound system has one or more speakers distributed within an MR space. MR device sound systems for users provides sound directly to the users wearing the MR devices. Audio signals representative of sound in the MR experience are mixed by each sound system to provide sounds that complement each other. Both sound systems provide sound to the users based on events occurring in the MR experience.

Abstract: Methods for producing an antibody or an antigen-binding fragment thereof specifically binding to an antigen of interest, methods for inducing proliferation of PBMCs, B cell activation and differentiation, B cell maturation, and/or promoting class switch in an antibody-producing PBMC to produce IgG, compositions for the in vitro immunization and methods for identifying an antibody-enhancing factor for in vitro immunization.

Abstract: Provided is an isolated TrkB agonist antibody that binds to an epitope contained in one of the extracellular domains of TrkB and is capable of activating TrkB, wherein the extracellular domains comprises extracellular D1, D2, D3, D4, D5 domains and juxtamembrane domain of TrkB. Methods of using the TrkB agonist antibody in treating or reducing the risk of a TrkB associated conditions in a subject, wherein said condition is selected from cell differentiation, synaptic development, neural injury repairing and/or neurite branching.

Abstract: Provided is an isolated TrkB agonist antibody that binds to an epitope contained in one of the extracellular domains of TrkB and is capable of activating TrkB, wherein the extracellular domains comprises extracellular D1, D2, D3, D4, D5 domains and juxtamembrane domain of TrkB. Methods of using the TrkB agonist antibody in treating or reducing the risk of a TrkB associated conditions in a subject, wherein said condition is selected from cell differentiation, synaptic development, neural injury repairing and/or neurite branching.

Abstract: Provided is an Alzheimer's disease rat model or a tissue or cell thereof, which comprises a chimeric APP gene encoding a modified APP and use thereof.

Abstract: Disclosed is a method for producing an antibody or an antigen-binding fragment thereof comprising a step of cultivating PBMCs in a medium comprising CD40L, ICOSL, ICOS, and/or TLR agonist. Also provided herein is a method for inducing proliferation of PBMCs, B cell activation and differentiation, and/or B cell maturation, comprising a step of cultivating PBMCs in a medium comprising IL2. Also provided herein is a method for promoting class switch in an antibody-producing PBMC to produce IgG, comprising a step of cultivating the antibody-producing PBMC in a medium comprising IL21.

Abstract: Provided is an isolated TrkB agonist antibody that binds to an epitope contained in one of the extracellular domains of TrkB and is capable of activating TrkB, wherein the extracellular domains comprises extracellular D1, D2, D3, D4, D5 domains and juxtamembrane domain of TrkB. Methods of using the TrkB agonist antibody in treating or reducing the risk of a TrkB associated conditions in a subject, wherein said condition is selected from cell differentiation, synaptic development, neural injury repairing and/or neurite branching.

Abstract: The invention is related to a novel primate specific brain isoform of the potassium channel KCNH2 and genetic association with risk for schizophrenia.

Abstract: The invention is related to a novel primate specific brain isoform of the potassium channel KCNH2 and genetic association with risk for schizophrenia.